Mind Medicine (MindMed) (MNMD) to Release Earnings on Thursday

Mind Medicine (MindMed) (NASDAQ:MNMD) is projected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Mind Medicine (MindMed) to post earnings of ($0.33) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Mind Medicine (MindMed) Price Performance

Shares of MNMD opened at $6.07 on Tuesday. The company has a market cap of $445.13 million, a price-to-earnings ratio of -2.69 and a beta of 2.59. Mind Medicine has a twelve month low of $5.03 and a twelve month high of $12.22. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $7.48 and a two-hundred day moving average of $6.91.

Insider Buying and Selling

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 19,106 shares of Mind Medicine (MindMed) stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $141,957.58. Following the completion of the transaction, the chief executive officer now owns 526,666 shares of the company’s stock, valued at approximately $3,913,128.38. The trade was a 3.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dan Karlin sold 6,643 shares of Mind Medicine (MindMed) stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total transaction of $49,357.49. Following the completion of the transaction, the insider now directly owns 338,013 shares of the company’s stock, valued at $2,511,436.59. The trade was a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,022 shares of company stock valued at $208,203 over the last 90 days. Insiders own 2.26% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Evercore ISI began coverage on shares of Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They set an “outperform” rating and a $23.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Mind Medicine (MindMed) in a research note on Friday, January 31st. Finally, Chardan Capital began coverage on shares of Mind Medicine (MindMed) in a research note on Friday, December 20th. They set a “buy” rating and a $20.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Mind Medicine (MindMed) presently has a consensus rating of “Buy” and an average price target of $26.33.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.